- Home
- CPBI vs RFL Comparison
CPBI vs RFL Comparison
Compare CPBI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CPBI | RFL |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 61.1M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CPBI | RFL |
|---|---|---|
| Price | $17.77 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.9K | ★ 77.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $13.00 | $1.12 |
| 52 Week High | $17.87 | $3.19 |
Technical Indicators
Market Signals| Indicator | CPBI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 61.62 |
| Support Level | $17.37 | $1.30 |
| Resistance Level | N/A | $1.44 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 80.00 | 47.49 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.